Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease.

Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease. - Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023243

Enrollment

Registered

2016-07-20

Start date

2016-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes meliitus

Interventions

Distribution to a group as administration of sitagliptin 25mg for three months, followed by administration of teneligliptin 20mg for three months Distribution to a group as administration of teneligli

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult type 2 diabetes patients Patients with renal function of eGFR 30~50ml/min/1.73m2, in oral teneligliptin 20mg non insulin dependent state patients patient's HbA1c are from 6 to 8 percent

Exclusion criteria

Exclusion criteria: Patients of both drugs is contraindicated Pregnancy, patients in nursing Patients suffering from a severe disease requiring hospitalization Patients with anemia (Hb <10g / dl) Patients undergoing steroid therapy Patients attending physician was found to be inappropriate for any reason

Design outcomes

Primary

Measure	Time frame
Changes in blood glucose and HbA1c	—

Countries

Japan

Contacts

Public ContactYASUO ZENIMARU

University of Fukui Hospital Department of Endocrinology and Metabolism

zenimaru@u-fukui.ac.jp0776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026